<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01782833</url>
  </required_header>
  <id_info>
    <org_study_id>021-KOA-1201n</org_study_id>
    <nct_id>NCT01782833</nct_id>
  </id_info>
  <brief_title>Pletaal SR Post Marketing Observational Study</brief_title>
  <acronym>PLT SR PMOS</acronym>
  <official_title>A Prospective, Post Marketing Observational Study to Evaluate the Safety of Pletaal® SR Capsule</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea Otsuka Pharmaceutical Co., Ltd.</source>
  <brief_summary>
    <textblock>
      This is a Post Marketing Observational Study of cilostazol (Pletaal® SR capsule). As this
      study is observational in nature to collect the safety data after administrating the Pletaal
      SR capsule, from baseline to 16 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be conducted in a prospective, single-arm, multi-center format. As this study
      is observational in nature, the patient's follow-up is not prescriptive in nature and must be
      left up to the judgment of the physician (investigator), within the period of observation set
      forth in the protocol.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence rate and the number of AE/ADRs</measure>
    <time_frame>Follow-up at least once from baseline to 16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence rate of Tarchycardia and Palpitation after Pletaal® SR capsule administration</measure>
    <time_frame>Follow-up at least once from baseline to 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number and percentage of drop-out patients according to Aes</measure>
    <time_frame>Follow-up at least once from baseline to 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference between AE and drug compliance according to patient's character</measure>
    <time_frame>Follow-up at least once from baseline to 16 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Treatment of Ischemic Symptom and Prevention of Recurrence of Cerebral Infarction</condition>
  <arm_group>
    <arm_group_label>Pletaal</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pletaal</intervention_name>
    <arm_group_label>Pletaal</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The patient who has below indication (1. Treatment of ischemic symptoms including
        ulceration, pain and coldness in chronic arterial occlusion (Berger's disease,
        arteriosclerosis obliterans, diabetic peripheral angiopathy). 2. Prevention of recurrence
        of cerebral infarction (excluding cardiogenic cerebral embolism).)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Patients must meet all of the following inclusion criteria to be eligible for enrollment
        into the study : 1. Patients who are prescribed Pletaal® SR capsule treatment as per
        investigator's medical judgment for adults aged 19 and over.

        2. Patients who gave written authorization to use their personal and health data Physician
        (Investigator) will refer to the product market authorization (package insert) for
        inclusion criteria.

        Exclusion Criteria:

          -  Patients presenting with any of the following will not be included in the study 1.
             Patients with hemorrhage 2. Patients with congestive heart failure 3. Patients with
             known hypersensitivity to Cilostazole or any ingredients of Pletaal® 4. Women who are
             pregnant or may possibly become pregnant 5. Patients who is not eligible to
             participate this study as investigator's medical judgment Physician (Investigator)
             will refer to the product market authorization (package insert) for exclusion
             criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ji Yoon Jung</last_name>
    </contact>
    <investigator>
      <last_name>Ji Yoon Jung</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NHIC Ilsan Hospital</name>
      <address>
        <city>Kyunggido Goyangsi</city>
        <zip>410-719</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jun Hong Lee</last_name>
    </contact>
    <investigator>
      <last_name>Jun Hong Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inje University Seoul Pail Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>100-032</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jae Myeon Jung</last_name>
    </contact>
    <investigator>
      <last_name>Jae Myeon Jung</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Man Ho Kim</last_name>
    </contact>
    <investigator>
      <last_name>Man Ho Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2013</study_first_submitted>
  <study_first_submitted_qc>January 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2013</study_first_posted>
  <last_update_submitted>January 31, 2013</last_update_submitted>
  <last_update_submitted_qc>January 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>January 14, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

